NextCure Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.48
- Today's High:
- $1.545
- Open Price:
- $1.48
- 52W Low:
- $1.16
- 52W High:
- $5.38
- Prev. Close:
- $1.49
- Volume:
- 56259
Company Statistics
- Market Cap.:
- $42.49 million
- Book Value:
- 6.032
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $-54199000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -22.25%
- Return on Equity TTM:
- -37.28%
Company Profile
NextCure Inc had its IPO on 2019-05-09 under the ticker symbol NXTC.
The company operates in the Healthcare sector and Biotechnology industry. NextCure Inc has a staff strength of 99 employees.
Stock update
Shares of NextCure Inc opened at $1.48 at the start of the last trading session i.e. 2023-03-31.
The stocks traded within a range of $1.48 - $1.55, and closed at $1.48.
This is a -0.67% slip from the previous day's closing price.
A total volume of 56,259 shares were traded at the close of the day’s session.
In the last one week, shares of NextCure Inc have slipped by -8.07%.
NextCure Inc's Key Ratios
NextCure Inc has a market cap of $42.49 million, indicating a price to book ratio of 0.2065 and a price to sales ratio of 9.5227.
In the last 12-months NextCure Inc’s revenue was $0 with a gross profit of $-54199000 and an EBITDA of $-71785000. The EBITDA ratio measures NextCure Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, NextCure Inc’s operating margin was 0% while its return on assets stood at -22.25% with a return of equity of -37.28%.
In Q4, NextCure Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.
NextCure Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.56 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into NextCure Inc’s profitability.
NextCure Inc stock is trading at a EV to sales ratio of 1.623 and a EV to EBITDA ratio of 3.0777. Its price to sales ratio in the trailing 12-months stood at 9.5227.
NextCure Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $184.16 million
- Total Liabilities
- $9.13 million
- Operating Cash Flow
- $4.47 million
- Capital Expenditure
- $865000
- Dividend Payout Ratio
- 0%
NextCure Inc ended 2023 with $184.16 million in total assets and $0 in total liabilities. Its intangible assets were valued at $184.16 million while shareholder equity stood at $167.53 million.
NextCure Inc ended 2023 with $0 in deferred long-term liabilities, $9.13 million in other current liabilities, 28000.00 in common stock, $-261759000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $26.63 million and cash and short-term investments were $159.91 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
NextCure Inc’s total current assets stands at $163.98 million while long-term investments were $0 and short-term investments were $133.28 million. Its net receivables were $0 compared to accounts payable of $4.27 million and inventory worth $0.
In 2023, NextCure Inc's operating cash flow was $4.47 million while its capital expenditure stood at $865000.
Comparatively, NextCure Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $1.48
- 52-Week High
- $5.38
- 52-Week Low
- $1.16
- Analyst Target Price
- $5.25
NextCure Inc stock is currently trading at $1.48 per share. It touched a 52-week high of $5.38 and a 52-week low of $5.38. Analysts tracking the stock have a 12-month average target price of $5.25.
Its 50-day moving average was $1.61 and 200-day moving average was $2.71 The short ratio stood at 3.29 indicating a short percent outstanding of 0%.
Around 875.8% of the company’s stock are held by insiders while 4912.9% are held by institutions.
Frequently Asked Questions About NextCure Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.